Form 4: Cryoport CEO Shelton Exercises Options, Sells Shares for Tax
Insider Transaction Report (Form 4)
Cryoport's President and CEO, Jerrell Shelton, reported the exercise of options for 25,000 common shares and the sale of 2,894 shares to cover tax obligations.
Summary
- Jerrell Shelton, President and CEO of Cryoport, Inc. (CYRX), reported transactions on March 23, 2026.
- Shelton exercised options to acquire 25,000 shares of common stock at an exercise price of $1.87 per share.
- Concurrently, 2,894 shares of common stock were sold at a price of $8.18 per share to satisfy tax obligations related to the vesting of restricted stock rights, as per company policy.
- Following these transactions, Shelton's direct beneficial ownership of common stock increased to 1,076,607 shares.
- Shelton also holds 154,007 options to purchase common stock directly.
- The options exercised were part of a grant that vested 1/48th monthly over forty-eight months, starting May 6, 2016, and are set to expire on May 6, 2026.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this filing as moderately positive. The CEO's exercise of a significant number of options, resulting in a net increase in his direct share ownership, signals confidence in Cryoport's valuation and future prospects, despite the routine sale of a smaller portion for tax purposes.
Positives
- The exercise of options by the CEO indicates confidence in the company's future, as it increases his direct equity stake.
- The exercise price of $1.87 per share is significantly lower than the sale price of $8.18 per share, suggesting a substantial in-the-money value for the options.
- Despite the sale for tax purposes, the net effect of these transactions is an increase of 22,106 shares in the CEO's direct beneficial ownership.
Negatives
- The sale of 2,894 shares, even for tax purposes, results in a reduction of the CEO's direct ownership, albeit a small portion compared to the options exercised.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding Cryoport's future financial performance or strategic direction.
Industry Context
StockSavvy.ai notes that insider transactions, particularly by a CEO, are closely watched by the market as they can provide insights into management's perception of the company's value. While routine tax-related sales are common, the exercise of options at a significantly lower price than the market value is generally viewed positively, suggesting the executive sees continued upside.
Stakeholder Impact
- Shareholders: The increase in CEO's direct ownership may be perceived as a positive signal, potentially boosting investor confidence.
- Employees: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 05/06/2016 | Start date for the monthly vesting of options (1/48th per month for 48 months). |
| 03/23/2026 | Transaction date for both the sale of common stock and the exercise of options. |
| 03/25/2026 | Date the Form 4 was signed by Jerrell Shelton. |
| 05/06/2026 | Expiration date for the options to purchase common stock. |
Keywords
Cryoport, CYRX, Jerrell Shelton, Insider Trading, Form 4, Stock Options, Share Sale, CEO Transactions, Biologistics, Life Sciences
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.